Literature DB >> 15953989

Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program.

Jan F Nygård1, Mari Nygård, Gry B Skare, Steinar Ø Thoresen.   

Abstract

OBJECTIVE: This study compares the screening history for women with cervical intraepithelial neoplasia (CIN) 2/3 or adenocarcinoma in situ (ACIS) with women with different stages and subtypes of cervical carcinoma.
METHODS: An analysis of the Norwegian Coordinated Cervical Screening Program comparing all cases with a CIN 2/3/ACIS (N=8586) with all ICC (N=777) in the period 2000-2002. All Pap smears since 1992 were used to characterise detection mode and screening history. Multinominal regression models estimated the risk associated with detection mode and adequate Pap smear history.
RESULTS: A wide range of age at diagnosis, from 16 to 92 years of age was observed regardless of the stage of the disease. Fifty five percentage of the women diagnosed with CIN 2/3/ACIS had an adequate screening history. Of women diagnosed with SCC, 45.1% in stage I, and 10.5% in stage IV had an adequate history. The median age of women with CIN 2/3 (34 years) and squamous cervical carcinoma (SCC) stage I (37 years) given an adequate Pap smear history was not significantly different. For women with ACC, the proportion with adequate screening history was roughly 50% for all stages. After adjustment for detection mode and age, the OR for being diagnosed with ICC stage I compared to CIN 2/3 was 1.2 (95% CI: 1.0-1.5), while the OR of being diagnosed with ICC stage II-IV was 3.4 (95% CI: 2.3-4.8).
CONCLUSIONS: Women with CIN 2/3 and ICC stage I were similar with respect to screening histories, i.e. detection mode and age at diagnosis, while women with ICC stage II-IV seldom had an adequate screening history and were diagnosed at a significantly higher age.

Entities:  

Mesh:

Year:  2005        PMID: 15953989     DOI: 10.1007/s10552-004-6295-z

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  14 in total

1.  Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer.

Authors:  Philip E Castle; Ana C Rodríguez; Robert D Burk; Rolando Herrero; Allan Hildesheim; Diane Solomon; Mark E Sherman; Jose Jeronimo; Mario Alfaro; Jorge Morales; Diego Guillén; Martha L Hutchinson; Sholom Wacholder; Mark Schiffman
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

Review 2.  The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.

Authors:  Theresa Guo; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

3.  Efficacy of a real time optoelectronic device (TruScreen™) in detecting cervical intraepithelial pathologies: a prospective observational study.

Authors:  Emre Özgü; Yunus Yıldız; Burçin Salman Özgü; Murat Öz; Nuri Danışman; Tayfun Güngör
Journal:  J Turk Ger Gynecol Assoc       Date:  2015-03-01

4.  The value of improving failures within a cervical cancer screening program: an example from Norway.

Authors:  Emily A Burger; Jane J Kim
Journal:  Int J Cancer       Date:  2014-03-20       Impact factor: 7.396

5.  Cervical Cancer Burden and Opportunities for Prevention in a Safety-Net Healthcare System.

Authors:  Sandi L Pruitt; Claudia L Werner; Eric K Borton; Joanne M Sanders; Bijal A Balasubramanian; Arti Barnes; Andrea C Betts; Celette Sugg Skinner; Jasmin A Tiro
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-05       Impact factor: 4.254

6.  Tubal ligation frequency in Oklahoma women with cervical cancer.

Authors:  Cara A Mathews; Julie A Stoner; Nicolas Wentzensen; Katherine M Moxley; Meaghan E Tenney; Erin R Tuller; Tashanna Myers; Lisa M Landrum; Grainger Lanneau; Rosemary E Zuna; Michael A Gold; Sophia S Wang; Joan L Walker
Journal:  Gynecol Oncol       Date:  2012-07-31       Impact factor: 5.482

7.  Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.

Authors:  Mari Nygård; Anne-Kjersti Daltveit; Steinar O Thoresen; Jan F Nygård
Journal:  BMC Health Serv Res       Date:  2007-01-23       Impact factor: 2.655

8.  Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.

Authors:  Raquel Ibáñez; María Alejo; Neus Combalia; Xavier Tarroch; Josefina Autonell; Laia Codina; Montserrat Culubret; Francesc Xavier Bosch; Silvia de Sanjosé
Journal:  Biomed Res Int       Date:  2015-06-09       Impact factor: 3.411

Review 9.  Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model.

Authors:  Ralph P Insinga; Erik J Dasbach; Elamin H Elbasha
Journal:  BMC Infect Dis       Date:  2009-07-29       Impact factor: 3.090

10.  Uterine cervix cancer treatment at Radiumhemmet: 90 years' experience. Time trends of age, stage, and histopathology distribution.

Authors:  Kristina Hellman; Ann-Cathrin Hellström; B Folke Pettersson
Journal:  Cancer Med       Date:  2014-01-14       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.